NASDAQ · KARDHealthcarePharmaceuticals

Kardigan financials

$14.21+0.57%
Close Nov 2, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Revenue$0.00
Gross profit$0.00
Gross margin—
Operating income-$119.0M
Net income-$116.2M
Net margin—
Diluted EPS$-4.61
EBITDA-$119.0M
Operating cash flow—
Free cash flow—
Diluted shares25.2M

Balance sheet

Period endJun 30
Cash & equivalents$384.0M
Short-term investments$213.6M
Total debt$0.00
Total assets$721.8M
Total liabilities$106.3M
Shareholders' equity$615.5M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology